CheckMate trials 648 and 649 explored various chemotherapy strategies for ESCC and GI cancer treatment. Syma Iqbal, MD: CheckMate 649 was a randomized trial for patients with untreated esophageal GEJ ...
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study. Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback